Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 8/20 | 0.74 |
| ▸ | JAK2 | O60674 | 7/20 | 0.74 |
| ▸ | TYK2 | P29597 | 2/20 | 0.74 |
| ▸ | JAK1 | P23458 | 7/20 | 0.62 |
| ▸ | BTK | Q06187 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822827 | 1.00 | JAK3 (0.74) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16822826 | 1.00 | JAK3 (0.74) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16514441 | 0.92 | BTK (0.63) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16823150 | 0.92 | BTK (0.63) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16515151 | 0.92 | BTK (0.63) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16515161 | 0.92 | JAK3 (0.62) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16514668 | 0.92 | JAK3 (0.62) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL29847584 | 0.92 | JAK3 (0.62) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16514665 | 0.92 | JAK3 (0.62) | JAK3JAK2TYK2JAK1BTK | |
| SCHEMBL16514250 | 0.90 | BTK (0.75) | JAK3JAK2TYK2JAK1BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | claimed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | claimed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | claimed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | claimed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | claimed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20200306259-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2020-10-01 | — | — | US | disclosed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2018-05-10 | — | — | US | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172868-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | JAK3 110/4885JAK2 53/4885TYK2 336/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20180125855-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20200306259-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | JAK3 335/4885JAK2 356/4885TYK2 239/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | JAK3 405/4885JAK2 248/4885TYK2 743/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | JAK3 161/4885JAK2 155/4885TYK2 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.